Malvern Panalytical unveils Zetasizer Pro and Ultra systems
Built on the heritage of the market-leading Zetasizer Nano range, and already the proud recipients of a Red Dot 2018 design award, these new flagship instruments deliver significant
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.
The patents, among other aspects, broadly cover compositions of matter of the inflammation-targeting microfiber materials with embedded molecules of interest. The platform is being evaluated for use across